Market Overview

BioClin Therapeutics Announces New Leadership to Advance Late-Stage Bladder Cancer Development Program

Share:

BioClin Therapeutics, Inc., a privately-held clinical stage drug
development company, today announced the appointment of Scott Myers as
Chief Executive Officer, and Julie Eastland as Chief Financial Officer
and Chief Business Officer. Mr. Myers will also continue in his role as
company Chairman.

"We are excited to announce the appointment of Scott Myers as Chief
Executive Officer," said David Kabakoff, Ph.D., Director of BioClin
Therapeutics and Executive Partner at Sofinnova Ventures. "Scott's track
record of leadership and shareholder value creation are an excellent fit
for our company."

"We are also pleased to announce the appointment of Julie Eastland as
our Chief Financial Officer and Chief Business Officer. Scott and Julie
previously partnered to successfully transform Cascadian Therapeutics,
leading to its acquisition by Seattle Genetics for $614M earlier this
year."

"On behalf of the entire board, I would like to thank our founding CEO
Stephen Lau, who is stepping down, for his exceptional contribution to
the company from inception to its current Phase 2 clinical stage. We are
grateful that he will continue to serve as an advisor to the company."

"I have been privileged to lead BioClin over the past 6 years and to
have advanced the development of B-701, which is a potential
best-in-class therapy for metastatic bladder cancer. I look forward to
supporting Scott and team during the transition," said Stephen Lau,
founder of BioClin Therapeutics.

"I'm delighted to welcome Julie Eastland to our management team as our
Chief Financial Officer and Chief Business Officer," said Scott Myers.
"Julie has a strong background in finance, business strategy and
licensing, having previously worked at a number of publicly traded and
private biotechnology companies. Her fundraising and business
development experience will prove invaluable as we execute on our
clinical development plans and enter the next phase of growth. Julie, I
and the entire management team are focused on advancing vofatamab
(B-701) into registration trials, keeping BioClin well-funded, and
strengthening the company's market profile."

Scott Myers was appointed Chairman of BioClin in June 2018. Mr. Myers
most recently served as CEO, President and Director of Seattle based,
Cascadian Therapeutics (NASDAQ:CASC), an oncology company that was
acquired by Seattle Genetics (NASDAQ:SGEN) in March 2018. Prior to
Cascadian, Mr. Myers was CEO of Aerocrine AB, a publicly-traded medical
device company based in Stockholm, Sweden and Morrisville, NC, that was
acquired by Circassia, PLC in 2015. Prior to Aerocrine, Mr. Myers held
senior commercial operations, business development, general management
and information management positions for UCB SA, a Belgium based
biopharmaceutical company, and Johnson & Johnson.

Julie Eastland most recently served as Chief Financial Officer and Chief
Business Officer of Cascadian Therapeutics, from September 2010 to May
2018, through the sale and transition of the company to Seattle
Genetics. From 2006 to 2010, Ms. Eastland was the Chief Financial
Officer and Vice President of Finance and Operations of VLST
Corporation, a privately-held biotechnology company. Prior to VLST, Ms.
Eastland held various financial and strategic management positions at
publicly-traded biotechnology companies including Dendreon and Amgen.

About BioClin Therapeutics

BioClin Therapeutics, Inc. is a privately-held, clinical stage
biotechnology company developing a targeted biologic for the potential
treatment of metastatic bladder cancer. The company is focused on
fibroblast growth factor receptor 3, (FGFR3), a driver of metastatic
bladder cancer and potentially other cancers. The company's lead
program, vofatamab, also known as B-701, is the only known targeted
biologic specific for FGFR3 in clinical development. BioClin has ongoing
clinical studies in metastatic bladder cancer including vofatamab
monotherapy, and vofatamab in combination with standard-of-care
chemotherapy, as well as with pembrolizumab, an immune checkpoint
inhibitor. BioClin's website is: www.bioclintherapeutics.com.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com